Sign up United Kingdom
Proactive Investors - Run By Investors For Investors

EKF Diagnostics shares soar on positive earnings and outlook

The Cardiff-based company said it had more than doubled its cash conversion over the last year
test tubes
EKF said it had secured a multi-million dollar enzyme contract and a distribution agreement with McKesson Medical-Surgical for its hemoglobin analyzer, DiaSpect

EKF Diagnostics Holdings PLC (LON:EKF) shares jumped more than 7% on Thursday after the medical equipment manufacturer said first-half earnings were ahead of its expectations and that it was confident that it would make further progress during the remainder of 2018.

The South Wales-based point-of-care company also said it had delivered extremely strong cash conversion - £9mln in the year to June 30 compared to £4mln in the same period a year earlier.

READ: Shares in EKF Diagnostics rise as underlying profits to be comfortably ahead of forecasts

In another positive development, EKF said that following significant investment in its Elkhart enzyme facility, it had secured a multi-million dollar enzyme contract with Oragenics, Inc. It added that it had also secured a distribution agreement with US-based McKesson Medical-Surgical for its haemoglobin analyser, DiaSpect, which recently received regulatory clearance.

In a note to clients, analysts at broker Finncap were positive on the tenders won by EKF and maintained its ‘buy’ recommendation on the stock.

Shares in EKF were up 7.6% at 39.48p in early afternoon trade.

View full EKF profile View Profile

EKF Diagnostics Timeline

Related Articles

Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
Drug discovery
April 04 2018
In the group’s 2017 results statement at the end of March, Ray Barlow - who took over as CEO on 6 April 2017 - commented: “We are now focused on the right activities"
pills
July 25 2018
Under former chief executive Peter George and his successor Shaun Chilton, Clinigen has been transformed via a series of well-judged, quickly integrated and cash generative acquisitions

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use